Brief: Prelude Therapeutics Says PRT3789 Generally Well-Tolerated With No Dose-Limiting Toxicities
13/09/2024 16:59
Sept 13 (Reuters) - Prelude Therapeutics Inc PRLD.O :
* PRELUDE THERAPEUTICS’ SMARCA2 DEGRADER PRT3789
DEMONSTRATED
PROMISING INITIAL CLINICAL ACTIVITY AND SAFETY PROFILE IN PHASE
1 TRIAL
* PRELUDE THERAPEUTICS INC - PRT3789 GENERALLY
WELL-TOLERATED WITH
NO DOSE-LIMITING TOXICITIES
Source text for Eikon: ID:nGNX7TlkY0
Further company coverage: PRLD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prelude Therapeutics Incorporated
See all newsBrief: Prelude Announces Clinical Trial Collaboration And Supply Agreement With Lilly To Evaluate KAT6A Selective Degrader PRT13722 In Combination With Verzenio® And Inluriyo® In Patients With HR+/HER2- Breast Cancer
U.S. RESEARCH ROUNDUP-Celcuity, Fluence Energy, Salesforce
Prelude Therapeutics Incorporated reports results for the quarter ended June 30 - Earnings Summary
Prelude Therapeutics Q2 revenue beats analyst expectations, net loss narrows
Prelude Therapeutics Incorporated expected to post a loss of 20 cents a share - Earnings Preview